nodes	percent_of_prediction	percent_of_DWPC	metapath
Nortriptyline—PTGS1—malignant glioma	0.501	1	CbGaD
Nortriptyline—CYP1A2—Carmustine—malignant glioma	0.0772	0.569	CbGbCtD
Nortriptyline—CYP3A4—Temozolomide—malignant glioma	0.0584	0.43	CbGbCtD
Nortriptyline—HTR2C—choroid plexus—malignant glioma	0.0165	0.13	CbGeAlD
Nortriptyline—HTR2A—choroid plexus—malignant glioma	0.00826	0.0654	CbGeAlD
Nortriptyline—ORM1—vertebral column—malignant glioma	0.00647	0.0512	CbGeAlD
Nortriptyline—HTR2C—telencephalic ventricle—malignant glioma	0.00482	0.0382	CbGeAlD
Nortriptyline—HTR2A—cerebellar cortex—malignant glioma	0.00416	0.0329	CbGeAlD
Nortriptyline—HTR1A—telencephalic ventricle—malignant glioma	0.00406	0.0321	CbGeAlD
Nortriptyline—DRD2—telencephalic ventricle—malignant glioma	0.00367	0.029	CbGeAlD
Nortriptyline—Tongue discolouration—Temozolomide—malignant glioma	0.00333	0.0399	CcSEcCtD
Nortriptyline—HTR2A—pons—malignant glioma	0.00294	0.0233	CbGeAlD
Nortriptyline—HTR2A—vertebral column—malignant glioma	0.00292	0.0231	CbGeAlD
Nortriptyline—HTR2A—telencephalic ventricle—malignant glioma	0.00242	0.0192	CbGeAlD
Nortriptyline—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00214	0.0256	CcSEcCtD
Nortriptyline—Cholestasis—Temozolomide—malignant glioma	0.00212	0.0254	CcSEcCtD
Nortriptyline—HTR2A—pineal body—malignant glioma	0.0021	0.0166	CbGeAlD
Nortriptyline—HTR6—telencephalon—malignant glioma	0.002	0.0159	CbGeAlD
Nortriptyline—Petechiae—Temozolomide—malignant glioma	0.00196	0.0234	CcSEcCtD
Nortriptyline—Coordination abnormal—Carmustine—malignant glioma	0.0017	0.0203	CcSEcCtD
Nortriptyline—Coordination abnormal—Temozolomide—malignant glioma	0.00164	0.0196	CcSEcCtD
Nortriptyline—ADRA1D—telencephalon—malignant glioma	0.00156	0.0124	CbGeAlD
Nortriptyline—Aplastic anaemia—Temozolomide—malignant glioma	0.00151	0.0181	CcSEcCtD
Nortriptyline—Gynaecomastia—Carmustine—malignant glioma	0.00149	0.0179	CcSEcCtD
Nortriptyline—PTGS1—endothelium—malignant glioma	0.00144	0.0114	CbGeAlD
Nortriptyline—Eye pain—Carmustine—malignant glioma	0.00134	0.016	CcSEcCtD
Nortriptyline—PTGS1—blood vessel—malignant glioma	0.00133	0.0105	CbGeAlD
Nortriptyline—Vascular purpura—Temozolomide—malignant glioma	0.00131	0.0156	CcSEcCtD
Nortriptyline—HTR2C—brainstem—malignant glioma	0.0013	0.0103	CbGeAlD
Nortriptyline—HTR2A—endothelium—malignant glioma	0.0013	0.0103	CbGeAlD
Nortriptyline—Eye pain—Temozolomide—malignant glioma	0.00129	0.0155	CcSEcCtD
Nortriptyline—CHRM4—central nervous system—malignant glioma	0.00127	0.0101	CbGeAlD
Nortriptyline—Hot flush—Temozolomide—malignant glioma	0.00125	0.015	CcSEcCtD
Nortriptyline—Menopausal symptoms—Temozolomide—malignant glioma	0.00124	0.0148	CcSEcCtD
Nortriptyline—SLC6A4—brainstem—malignant glioma	0.00124	0.0098	CbGeAlD
Nortriptyline—Purpura—Temozolomide—malignant glioma	0.00121	0.0145	CcSEcCtD
Nortriptyline—CHRM2—telencephalon—malignant glioma	0.0012	0.00951	CbGeAlD
Nortriptyline—HTR2A—blood vessel—malignant glioma	0.0012	0.00948	CbGeAlD
Nortriptyline—HTR2C—telencephalon—malignant glioma	0.00116	0.00917	CbGeAlD
Nortriptyline—HTR6—central nervous system—malignant glioma	0.00114	0.00902	CbGeAlD
Nortriptyline—Ataxia—Carmustine—malignant glioma	0.00114	0.0136	CcSEcCtD
Nortriptyline—Ataxia—Temozolomide—malignant glioma	0.0011	0.0132	CcSEcCtD
Nortriptyline—HTR1A—brainstem—malignant glioma	0.0011	0.0087	CbGeAlD
Nortriptyline—SLC6A4—telencephalon—malignant glioma	0.0011	0.00869	CbGeAlD
Nortriptyline—CHRM1—telencephalon—malignant glioma	0.00109	0.00866	CbGeAlD
Nortriptyline—SLC6A2—brainstem—malignant glioma	0.00109	0.00862	CbGeAlD
Nortriptyline—Amitriptyline—NTRK2—malignant glioma	0.00109	0.141	CrCbGaD
Nortriptyline—ADRA1A—brainstem—malignant glioma	0.00101	0.00802	CbGeAlD
Nortriptyline—CHRM4—brain—malignant glioma	0.00101	0.008	CbGeAlD
Nortriptyline—CHRM5—central nervous system—malignant glioma	0.000995	0.00788	CbGeAlD
Nortriptyline—Pancytopenia—Carmustine—malignant glioma	0.000992	0.0119	CcSEcCtD
Nortriptyline—DRD2—brainstem—malignant glioma	0.000992	0.00786	CbGeAlD
Nortriptyline—Sweating increased—Temozolomide—malignant glioma	0.000984	0.0118	CcSEcCtD
Nortriptyline—CHRM3—telencephalon—malignant glioma	0.000979	0.00775	CbGeAlD
Nortriptyline—HTR1A—telencephalon—malignant glioma	0.000975	0.00772	CbGeAlD
Nortriptyline—SLC6A2—telencephalon—malignant glioma	0.000966	0.00765	CbGeAlD
Nortriptyline—Pancytopenia—Temozolomide—malignant glioma	0.000959	0.0115	CcSEcCtD
Nortriptyline—DRD2—retina—malignant glioma	0.000957	0.00758	CbGeAlD
Nortriptyline—Pollakiuria—Temozolomide—malignant glioma	0.000933	0.0112	CcSEcCtD
Nortriptyline—Erectile dysfunction—Temozolomide—malignant glioma	0.00093	0.0111	CcSEcCtD
Nortriptyline—Weight increased—Temozolomide—malignant glioma	0.000919	0.011	CcSEcCtD
Nortriptyline—Weight decreased—Temozolomide—malignant glioma	0.000914	0.0109	CcSEcCtD
Nortriptyline—Neuropathy peripheral—Carmustine—malignant glioma	0.000913	0.0109	CcSEcCtD
Nortriptyline—HTR2C—medulla oblongata—malignant glioma	0.00091	0.00721	CbGeAlD
Nortriptyline—ADRA1B—central nervous system—malignant glioma	0.000909	0.0072	CbGeAlD
Nortriptyline—Stomatitis—Carmustine—malignant glioma	0.000908	0.0109	CcSEcCtD
Nortriptyline—HTR6—brain—malignant glioma	0.000904	0.00716	CbGeAlD
Nortriptyline—ORM1—spinal cord—malignant glioma	0.000903	0.00715	CbGeAlD
Nortriptyline—ADRA1A—telencephalon—malignant glioma	0.000898	0.00712	CbGeAlD
Nortriptyline—ADRA1D—central nervous system—malignant glioma	0.000889	0.00704	CbGeAlD
Nortriptyline—Neuropathy peripheral—Temozolomide—malignant glioma	0.000883	0.0106	CcSEcCtD
Nortriptyline—DRD2—telencephalon—malignant glioma	0.000881	0.00697	CbGeAlD
Nortriptyline—Stomatitis—Temozolomide—malignant glioma	0.000878	0.0105	CcSEcCtD
Nortriptyline—Hallucination—Carmustine—malignant glioma	0.000832	0.00997	CcSEcCtD
Nortriptyline—Hypoaesthesia—Carmustine—malignant glioma	0.000832	0.00997	CcSEcCtD
Nortriptyline—HTR2C—midbrain—malignant glioma	0.000831	0.00659	CbGeAlD
Nortriptyline—Oedema peripheral—Carmustine—malignant glioma	0.000824	0.00987	CcSEcCtD
Nortriptyline—Epinastine—CYP2B6—malignant glioma	0.00082	0.107	CrCbGaD
Nortriptyline—HTR2C—spinal cord—malignant glioma	0.000811	0.00642	CbGeAlD
Nortriptyline—Hepatitis—Temozolomide—malignant glioma	0.000808	0.00968	CcSEcCtD
Nortriptyline—Hypoaesthesia—Temozolomide—malignant glioma	0.000804	0.00963	CcSEcCtD
Nortriptyline—Hallucination—Temozolomide—malignant glioma	0.000804	0.00963	CcSEcCtD
Nortriptyline—Oedema peripheral—Temozolomide—malignant glioma	0.000796	0.00954	CcSEcCtD
Nortriptyline—CHRM5—brain—malignant glioma	0.00079	0.00625	CbGeAlD
Nortriptyline—SLC6A4—midbrain—malignant glioma	0.000788	0.00624	CbGeAlD
Nortriptyline—Eye disorder—Carmustine—malignant glioma	0.000782	0.00936	CcSEcCtD
Nortriptyline—Flushing—Carmustine—malignant glioma	0.000776	0.0093	CcSEcCtD
Nortriptyline—SLC6A4—spinal cord—malignant glioma	0.000769	0.00609	CbGeAlD
Nortriptyline—SLC6A2—medulla oblongata—malignant glioma	0.000759	0.00601	CbGeAlD
Nortriptyline—Eye disorder—Temozolomide—malignant glioma	0.000755	0.00905	CcSEcCtD
Nortriptyline—Tinnitus—Temozolomide—malignant glioma	0.000754	0.00903	CcSEcCtD
Nortriptyline—Flushing—Temozolomide—malignant glioma	0.00075	0.00899	CcSEcCtD
Nortriptyline—Arrhythmia—Carmustine—malignant glioma	0.000747	0.00895	CcSEcCtD
Nortriptyline—Alopecia—Carmustine—malignant glioma	0.000739	0.00885	CcSEcCtD
Nortriptyline—ORM1—central nervous system—malignant glioma	0.000732	0.0058	CbGeAlD
Nortriptyline—ADRA1B—brain—malignant glioma	0.000722	0.00571	CbGeAlD
Nortriptyline—Alopecia—Temozolomide—malignant glioma	0.000714	0.00856	CcSEcCtD
Nortriptyline—HTR2A—embryo—malignant glioma	0.000714	0.00566	CbGeAlD
Nortriptyline—ADRA1D—brain—malignant glioma	0.000706	0.00559	CbGeAlD
Nortriptyline—HTR1A—midbrain—malignant glioma	0.0007	0.00554	CbGeAlD
Nortriptyline—HRH1—telencephalon—malignant glioma	0.000695	0.00551	CbGeAlD
Nortriptyline—Dysgeusia—Temozolomide—malignant glioma	0.000689	0.00825	CcSEcCtD
Nortriptyline—Vision blurred—Carmustine—malignant glioma	0.000686	0.00822	CcSEcCtD
Nortriptyline—HTR1A—spinal cord—malignant glioma	0.000683	0.00541	CbGeAlD
Nortriptyline—CHRM2—central nervous system—malignant glioma	0.000683	0.00541	CbGeAlD
Nortriptyline—Tremor—Carmustine—malignant glioma	0.000682	0.00817	CcSEcCtD
Nortriptyline—Amitriptyline—NTRK1—malignant glioma	0.000671	0.0874	CrCbGaD
Nortriptyline—Agitation—Carmustine—malignant glioma	0.000669	0.00801	CcSEcCtD
Nortriptyline—CYP2E1—telencephalon—malignant glioma	0.000668	0.00529	CbGeAlD
Nortriptyline—Vision blurred—Temozolomide—malignant glioma	0.000663	0.00794	CcSEcCtD
Nortriptyline—Tremor—Temozolomide—malignant glioma	0.000659	0.0079	CcSEcCtD
Nortriptyline—HTR2C—central nervous system—malignant glioma	0.000658	0.00521	CbGeAlD
Nortriptyline—HTR2A—brainstem—malignant glioma	0.000654	0.00518	CbGeAlD
Nortriptyline—Ill-defined disorder—Temozolomide—malignant glioma	0.000653	0.00782	CcSEcCtD
Nortriptyline—Leukopenia—Carmustine—malignant glioma	0.000652	0.00781	CcSEcCtD
Nortriptyline—Agitation—Temozolomide—malignant glioma	0.000647	0.00775	CcSEcCtD
Nortriptyline—PTGS1—telencephalon—malignant glioma	0.000644	0.0051	CbGeAlD
Nortriptyline—Malaise—Temozolomide—malignant glioma	0.000635	0.0076	CcSEcCtD
Nortriptyline—DRD2—midbrain—malignant glioma	0.000632	0.00501	CbGeAlD
Nortriptyline—HTR2A—retina—malignant glioma	0.000631	0.005	CbGeAlD
Nortriptyline—Convulsion—Carmustine—malignant glioma	0.000631	0.00756	CcSEcCtD
Nortriptyline—Leukopenia—Temozolomide—malignant glioma	0.00063	0.00754	CcSEcCtD
Nortriptyline—Hypertension—Carmustine—malignant glioma	0.000629	0.00753	CcSEcCtD
Nortriptyline—SLC6A4—central nervous system—malignant glioma	0.000624	0.00494	CbGeAlD
Nortriptyline—Palpitations—Temozolomide—malignant glioma	0.000622	0.00745	CcSEcCtD
Nortriptyline—CHRM1—central nervous system—malignant glioma	0.000622	0.00492	CbGeAlD
Nortriptyline—Anxiety—Carmustine—malignant glioma	0.000618	0.0074	CcSEcCtD
Nortriptyline—Convulsion—Temozolomide—malignant glioma	0.00061	0.0073	CcSEcCtD
Nortriptyline—Hypertension—Temozolomide—malignant glioma	0.000608	0.00728	CcSEcCtD
Nortriptyline—Maprotiline—SLC6A3—malignant glioma	0.000601	0.0783	CrCbGaD
Nortriptyline—Confusional state—Carmustine—malignant glioma	0.000599	0.00718	CcSEcCtD
Nortriptyline—Anxiety—Temozolomide—malignant glioma	0.000597	0.00715	CcSEcCtD
Nortriptyline—CYP2D6—brainstem—malignant glioma	0.000596	0.00472	CbGeAlD
Nortriptyline—Oedema—Carmustine—malignant glioma	0.000594	0.00712	CcSEcCtD
Nortriptyline—Discomfort—Temozolomide—malignant glioma	0.000592	0.00709	CcSEcCtD
Nortriptyline—Dry mouth—Temozolomide—malignant glioma	0.000586	0.00702	CcSEcCtD
Nortriptyline—Thrombocytopenia—Carmustine—malignant glioma	0.000582	0.00697	CcSEcCtD
Nortriptyline—HTR2A—telencephalon—malignant glioma	0.000581	0.0046	CbGeAlD
Nortriptyline—Tachycardia—Carmustine—malignant glioma	0.00058	0.00695	CcSEcCtD
Nortriptyline—Confusional state—Temozolomide—malignant glioma	0.000579	0.00694	CcSEcCtD
Nortriptyline—Oedema—Temozolomide—malignant glioma	0.000574	0.00688	CcSEcCtD
Nortriptyline—Anorexia—Carmustine—malignant glioma	0.000566	0.00679	CcSEcCtD
Nortriptyline—Thrombocytopenia—Temozolomide—malignant glioma	0.000562	0.00674	CcSEcCtD
Nortriptyline—CHRM3—central nervous system—malignant glioma	0.000556	0.0044	CbGeAlD
Nortriptyline—Hypotension—Carmustine—malignant glioma	0.000555	0.00665	CcSEcCtD
Nortriptyline—Hyperhidrosis—Temozolomide—malignant glioma	0.000555	0.00665	CcSEcCtD
Nortriptyline—HTR1A—central nervous system—malignant glioma	0.000554	0.00439	CbGeAlD
Nortriptyline—SLC6A2—central nervous system—malignant glioma	0.000549	0.00435	CbGeAlD
Nortriptyline—Anorexia—Temozolomide—malignant glioma	0.000547	0.00656	CcSEcCtD
Nortriptyline—CHRM2—brain—malignant glioma	0.000542	0.00429	CbGeAlD
Nortriptyline—HTR1A—cerebellum—malignant glioma	0.000541	0.00429	CbGeAlD
Nortriptyline—Insomnia—Carmustine—malignant glioma	0.000537	0.00644	CcSEcCtD
Nortriptyline—Paraesthesia—Carmustine—malignant glioma	0.000534	0.00639	CcSEcCtD
Nortriptyline—CYP2D6—telencephalon—malignant glioma	0.000529	0.00419	CbGeAlD
Nortriptyline—Somnolence—Carmustine—malignant glioma	0.000528	0.00633	CcSEcCtD
Nortriptyline—CYP2E1—medulla oblongata—malignant glioma	0.000525	0.00416	CbGeAlD
Nortriptyline—HTR2C—brain—malignant glioma	0.000522	0.00414	CbGeAlD
Nortriptyline—Insomnia—Temozolomide—malignant glioma	0.000519	0.00622	CcSEcCtD
Nortriptyline—Decreased appetite—Carmustine—malignant glioma	0.000517	0.00619	CcSEcCtD
Nortriptyline—Clomipramine—GSTP1—malignant glioma	0.000516	0.0671	CrCbGaD
Nortriptyline—Paraesthesia—Temozolomide—malignant glioma	0.000516	0.00618	CcSEcCtD
Nortriptyline—ADRA1A—central nervous system—malignant glioma	0.000511	0.00404	CbGeAlD
Nortriptyline—Somnolence—Temozolomide—malignant glioma	0.000511	0.00612	CcSEcCtD
Nortriptyline—ALB—brain—malignant glioma	0.00051	0.00404	CbGeAlD
Nortriptyline—Constipation—Carmustine—malignant glioma	0.000508	0.00609	CcSEcCtD
Nortriptyline—Dyspepsia—Temozolomide—malignant glioma	0.000506	0.00606	CcSEcCtD
Nortriptyline—DRD2—central nervous system—malignant glioma	0.000501	0.00396	CbGeAlD
Nortriptyline—Decreased appetite—Temozolomide—malignant glioma	0.000499	0.00598	CcSEcCtD
Nortriptyline—ADRA1A—cerebellum—malignant glioma	0.000499	0.00395	CbGeAlD
Nortriptyline—SLC6A4—brain—malignant glioma	0.000495	0.00392	CbGeAlD
Nortriptyline—Fatigue—Temozolomide—malignant glioma	0.000495	0.00593	CcSEcCtD
Nortriptyline—CHRM1—brain—malignant glioma	0.000493	0.00391	CbGeAlD
Nortriptyline—Constipation—Temozolomide—malignant glioma	0.000491	0.00588	CcSEcCtD
Nortriptyline—Feeling abnormal—Carmustine—malignant glioma	0.00049	0.00587	CcSEcCtD
Nortriptyline—DRD2—cerebellum—malignant glioma	0.000489	0.00387	CbGeAlD
Nortriptyline—Mianserin—CYP2B6—malignant glioma	0.000474	0.0617	CrCbGaD
Nortriptyline—Feeling abnormal—Temozolomide—malignant glioma	0.000473	0.00567	CcSEcCtD
Nortriptyline—Desipramine—CYP2C18—malignant glioma	0.00047	0.0612	CrCbGaD
Nortriptyline—Body temperature increased—Carmustine—malignant glioma	0.00047	0.00563	CcSEcCtD
Nortriptyline—Abdominal pain—Carmustine—malignant glioma	0.00047	0.00563	CcSEcCtD
Nortriptyline—CYP2E1—spinal cord—malignant glioma	0.000468	0.00371	CbGeAlD
Nortriptyline—HTR2A—medulla oblongata—malignant glioma	0.000456	0.00361	CbGeAlD
Nortriptyline—Urticaria—Temozolomide—malignant glioma	0.000456	0.00546	CcSEcCtD
Nortriptyline—Body temperature increased—Temozolomide—malignant glioma	0.000454	0.00544	CcSEcCtD
Nortriptyline—Abdominal pain—Temozolomide—malignant glioma	0.000454	0.00544	CcSEcCtD
Nortriptyline—PTGS1—spinal cord—malignant glioma	0.000451	0.00357	CbGeAlD
Nortriptyline—CHRM3—brain—malignant glioma	0.000442	0.0035	CbGeAlD
Nortriptyline—HTR1A—brain—malignant glioma	0.00044	0.00348	CbGeAlD
Nortriptyline—Hypersensitivity—Carmustine—malignant glioma	0.000438	0.00524	CcSEcCtD
Nortriptyline—SLC6A2—brain—malignant glioma	0.000436	0.00345	CbGeAlD
Nortriptyline—Asthenia—Carmustine—malignant glioma	0.000426	0.00511	CcSEcCtD
Nortriptyline—Hypersensitivity—Temozolomide—malignant glioma	0.000423	0.00507	CcSEcCtD
Nortriptyline—HTR2A—midbrain—malignant glioma	0.000417	0.0033	CbGeAlD
Nortriptyline—Atomoxetine—SLC6A3—malignant glioma	0.000413	0.0538	CrCbGaD
Nortriptyline—Asthenia—Temozolomide—malignant glioma	0.000412	0.00494	CcSEcCtD
Nortriptyline—HTR2A—spinal cord—malignant glioma	0.000407	0.00322	CbGeAlD
Nortriptyline—Diarrhoea—Carmustine—malignant glioma	0.000407	0.00487	CcSEcCtD
Nortriptyline—Pruritus—Temozolomide—malignant glioma	0.000406	0.00487	CcSEcCtD
Nortriptyline—ADRA1A—brain—malignant glioma	0.000405	0.00321	CbGeAlD
Nortriptyline—Mianserin—SLC6A3—malignant glioma	0.000404	0.0526	CrCbGaD
Nortriptyline—Imipramine—CYP2C18—malignant glioma	0.000399	0.0519	CrCbGaD
Nortriptyline—DRD2—brain—malignant glioma	0.000397	0.00315	CbGeAlD
Nortriptyline—HRH1—central nervous system—malignant glioma	0.000395	0.00313	CbGeAlD
Nortriptyline—Dizziness—Carmustine—malignant glioma	0.000393	0.00471	CcSEcCtD
Nortriptyline—Diarrhoea—Temozolomide—malignant glioma	0.000393	0.00471	CcSEcCtD
Nortriptyline—CYP2E1—central nervous system—malignant glioma	0.00038	0.00301	CbGeAlD
Nortriptyline—Dizziness—Temozolomide—malignant glioma	0.00038	0.00455	CcSEcCtD
Nortriptyline—Vomiting—Carmustine—malignant glioma	0.000378	0.00453	CcSEcCtD
Nortriptyline—Rash—Carmustine—malignant glioma	0.000375	0.00449	CcSEcCtD
Nortriptyline—Dermatitis—Carmustine—malignant glioma	0.000374	0.00448	CcSEcCtD
Nortriptyline—Headache—Carmustine—malignant glioma	0.000372	0.00446	CcSEcCtD
Nortriptyline—CYP2E1—cerebellum—malignant glioma	0.000371	0.00294	CbGeAlD
Nortriptyline—PTGS1—central nervous system—malignant glioma	0.000366	0.0029	CbGeAlD
Nortriptyline—Vomiting—Temozolomide—malignant glioma	0.000365	0.00437	CcSEcCtD
Nortriptyline—Rash—Temozolomide—malignant glioma	0.000362	0.00434	CcSEcCtD
Nortriptyline—Dermatitis—Temozolomide—malignant glioma	0.000362	0.00433	CcSEcCtD
Nortriptyline—Headache—Temozolomide—malignant glioma	0.00036	0.00431	CcSEcCtD
Nortriptyline—Nausea—Carmustine—malignant glioma	0.000353	0.00423	CcSEcCtD
Nortriptyline—Desipramine—CYP2B6—malignant glioma	0.000349	0.0454	CrCbGaD
Nortriptyline—Nausea—Temozolomide—malignant glioma	0.000341	0.00409	CcSEcCtD
Nortriptyline—Trimipramine—SLC6A3—malignant glioma	0.00034	0.0443	CrCbGaD
Nortriptyline—HTR2A—central nervous system—malignant glioma	0.00033	0.00261	CbGeAlD
Nortriptyline—HTR2A—cerebellum—malignant glioma	0.000323	0.00256	CbGeAlD
Nortriptyline—HRH1—brain—malignant glioma	0.000314	0.00249	CbGeAlD
Nortriptyline—CYP3A4—central nervous system—malignant glioma	0.000306	0.00242	CbGeAlD
Nortriptyline—CYP2E1—brain—malignant glioma	0.000302	0.00239	CbGeAlD
Nortriptyline—CYP2D6—central nervous system—malignant glioma	0.000301	0.00238	CbGeAlD
Nortriptyline—Desipramine—SLC6A3—malignant glioma	0.000297	0.0387	CrCbGaD
Nortriptyline—Imipramine—CYP2B6—malignant glioma	0.000296	0.0385	CrCbGaD
Nortriptyline—Amitriptyline—CYP2B6—malignant glioma	0.000294	0.0383	CrCbGaD
Nortriptyline—CYP2D6—cerebellum—malignant glioma	0.000294	0.00233	CbGeAlD
Nortriptyline—PTGS1—brain—malignant glioma	0.00029	0.0023	CbGeAlD
Nortriptyline—HTR2A—brain—malignant glioma	0.000262	0.00208	CbGeAlD
Nortriptyline—Imipramine—SLC6A3—malignant glioma	0.000252	0.0328	CrCbGaD
Nortriptyline—CYP2D6—brain—malignant glioma	0.000239	0.00189	CbGeAlD
Nortriptyline—CHRM3—Signaling Pathways—MDM2—malignant glioma	6.31e-06	4.32e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—RAF1—malignant glioma	6.31e-06	4.32e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—PIK3CB—malignant glioma	6.29e-06	4.31e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—CAV1—malignant glioma	6.29e-06	4.31e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—RAF1—malignant glioma	6.29e-06	4.31e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—MYC—malignant glioma	6.28e-06	4.3e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—CASP3—malignant glioma	6.28e-06	4.3e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—ERBB2—malignant glioma	6.27e-06	4.3e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling by GPCR—PIK3CA—malignant glioma	6.27e-06	4.3e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—IL2—malignant glioma	6.27e-06	4.29e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—ERBB2—malignant glioma	6.26e-06	4.29e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling by GPCR—PIK3CA—malignant glioma	6.26e-06	4.29e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—MDM2—malignant glioma	6.25e-06	4.28e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—ERBB2—malignant glioma	6.24e-06	4.27e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—CAV1—malignant glioma	6.23e-06	4.27e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—MDM2—malignant glioma	6.23e-06	4.27e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—MMP9—malignant glioma	6.23e-06	4.27e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PIK3CG—malignant glioma	6.23e-06	4.27e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—RAF1—malignant glioma	6.23e-06	4.27e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—ERBB2—malignant glioma	6.22e-06	4.26e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—RAF1—malignant glioma	6.21e-06	4.25e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—MMP9—malignant glioma	6.2e-06	4.25e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—PTEN—malignant glioma	6.19e-06	4.24e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	6.19e-06	4.24e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—PIK3CB—malignant glioma	6.19e-06	4.24e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—PIK3CB—malignant glioma	6.18e-06	4.23e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—PIK3CB—malignant glioma	6.17e-06	4.23e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—PTEN—malignant glioma	6.16e-06	4.22e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—ERBB2—malignant glioma	6.16e-06	4.22e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—PIK3CB—malignant glioma	6.16e-06	4.22e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—ERBB2—malignant glioma	6.14e-06	4.21e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—EGFR—malignant glioma	6.14e-06	4.21e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—PIK3CB—malignant glioma	6.14e-06	4.21e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—PTGS2—malignant glioma	6.13e-06	4.2e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—PTGS2—malignant glioma	6.12e-06	4.19e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—PIK3CD—malignant glioma	6.1e-06	4.18e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—PIK3CB—malignant glioma	6.08e-06	4.16e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—PIK3CB—malignant glioma	6.06e-06	4.15e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—KRAS—malignant glioma	6.06e-06	4.15e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—CXCL8—malignant glioma	6.05e-06	4.14e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling by GPCR—AKT1—malignant glioma	6.04e-06	4.14e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PPARG—malignant glioma	6.01e-06	4.12e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling by GPCR—AKT1—malignant glioma	6.01e-06	4.12e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.96e-06	4.08e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—CXCL8—malignant glioma	5.95e-06	4.08e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—CXCL8—malignant glioma	5.94e-06	4.07e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—MMP9—malignant glioma	5.93e-06	4.06e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—CXCL8—malignant glioma	5.92e-06	4.05e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—MYC—malignant glioma	5.91e-06	4.05e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—PIK3CA—malignant glioma	5.9e-06	4.04e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—CXCL8—malignant glioma	5.9e-06	4.04e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—PTEN—malignant glioma	5.9e-06	4.04e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—CXCL8—malignant glioma	5.84e-06	4e-05	CbGpPWpGaD
Nortriptyline—DRD2—GPCR downstream signaling—AKT1—malignant glioma	5.84e-06	4e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—CXCL8—malignant glioma	5.83e-06	3.99e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—KRAS—malignant glioma	5.8e-06	3.98e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—CASP3—malignant glioma	5.79e-06	3.96e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—IL2—malignant glioma	5.78e-06	3.96e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—EGFR—malignant glioma	5.78e-06	3.96e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling by GPCR—AKT1—malignant glioma	5.75e-06	3.94e-05	CbGpPWpGaD
Nortriptyline—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	5.75e-06	3.94e-05	CbGpPWpGaD
Nortriptyline—HRH1—GPCR downstream signaling—AKT1—malignant glioma	5.74e-06	3.93e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PIK3CG—malignant glioma	5.73e-06	3.92e-05	CbGpPWpGaD
Nortriptyline—CHRM1—GPCR downstream signaling—AKT1—malignant glioma	5.72e-06	3.92e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—TP53—malignant glioma	5.71e-06	3.91e-05	CbGpPWpGaD
Nortriptyline—CHRM3—GPCR downstream signaling—AKT1—malignant glioma	5.7e-06	3.9e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—CASP3—malignant glioma	5.69e-06	3.9e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—IL2—malignant glioma	5.69e-06	3.9e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—CASP3—malignant glioma	5.68e-06	3.89e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PIK3CG—malignant glioma	5.68e-06	3.89e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—IL2—malignant glioma	5.67e-06	3.89e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—CASP3—malignant glioma	5.66e-06	3.88e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—IL2—malignant glioma	5.66e-06	3.87e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—CASP3—malignant glioma	5.65e-06	3.87e-05	CbGpPWpGaD
Nortriptyline—CHRM2—GPCR downstream signaling—AKT1—malignant glioma	5.64e-06	3.87e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—IL2—malignant glioma	5.64e-06	3.86e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—GPCR downstream signaling—AKT1—malignant glioma	5.63e-06	3.86e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—VEGFA—malignant glioma	5.59e-06	3.83e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—CASP3—malignant glioma	5.59e-06	3.83e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—IL2—malignant glioma	5.58e-06	3.82e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—CASP3—malignant glioma	5.58e-06	3.82e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—IL2—malignant glioma	5.57e-06	3.81e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—PIK3CA—malignant glioma	5.57e-06	3.81e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—VEGFA—malignant glioma	5.56e-06	3.81e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—STAT3—malignant glioma	5.54e-06	3.79e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PPARG—malignant glioma	5.53e-06	3.79e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—STAT3—malignant glioma	5.51e-06	3.77e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—GSTP1—malignant glioma	5.49e-06	3.76e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PPARG—malignant glioma	5.48e-06	3.75e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PIK3CD—malignant glioma	5.48e-06	3.75e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—MMP9—malignant glioma	5.47e-06	3.75e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—KRAS—malignant glioma	5.46e-06	3.74e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—PTEN—malignant glioma	5.44e-06	3.72e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—TP53—malignant glioma	5.39e-06	3.69e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—MMP9—malignant glioma	5.38e-06	3.69e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—MMP9—malignant glioma	5.37e-06	3.68e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—MMP9—malignant glioma	5.35e-06	3.67e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—PTEN—malignant glioma	5.35e-06	3.67e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—PTEN—malignant glioma	5.35e-06	3.66e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—CAT—malignant glioma	5.34e-06	3.66e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—PTEN—malignant glioma	5.34e-06	3.66e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—MMP9—malignant glioma	5.34e-06	3.66e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—PTEN—malignant glioma	5.33e-06	3.65e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—PIK3CA—malignant glioma	5.33e-06	3.65e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—CAV1—malignant glioma	5.33e-06	3.65e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—VEGFA—malignant glioma	5.33e-06	3.65e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—PTEN—malignant glioma	5.32e-06	3.65e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—PIK3CB—malignant glioma	5.32e-06	3.64e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling by GPCR—AKT1—malignant glioma	5.3e-06	3.63e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—PTEN—malignant glioma	5.3e-06	3.63e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—MMP9—malignant glioma	5.28e-06	3.62e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—STAT3—malignant glioma	5.27e-06	3.61e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—MMP9—malignant glioma	5.27e-06	3.61e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—PTGS2—malignant glioma	5.27e-06	3.61e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—PTEN—malignant glioma	5.25e-06	3.6e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—PTEN—malignant glioma	5.24e-06	3.59e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling by GPCR—AKT1—malignant glioma	5.22e-06	3.58e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling by GPCR—AKT1—malignant glioma	5.21e-06	3.57e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling by GPCR—AKT1—malignant glioma	5.19e-06	3.56e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling by GPCR—AKT1—malignant glioma	5.18e-06	3.55e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—TP53—malignant glioma	5.16e-06	3.53e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—MYC—malignant glioma	5.15e-06	3.53e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling by GPCR—AKT1—malignant glioma	5.12e-06	3.51e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—MYC—malignant glioma	5.12e-06	3.51e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling by GPCR—AKT1—malignant glioma	5.11e-06	3.5e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.09e-06	3.49e-05	CbGpPWpGaD
Nortriptyline—PTGS1—Metabolism—PIK3CA—malignant glioma	5.05e-06	3.46e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—NCOR1—malignant glioma	5.04e-06	3.46e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PIK3CD—malignant glioma	5.04e-06	3.45e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—EGFR—malignant glioma	5.03e-06	3.45e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—PIK3CA—malignant glioma	5.01e-06	3.43e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—EGFR—malignant glioma	5.01e-06	3.43e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PIK3CD—malignant glioma	4.99e-06	3.42e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—VEGFA—malignant glioma	4.91e-06	3.36e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—MYC—malignant glioma	4.9e-06	3.36e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—STAT3—malignant glioma	4.86e-06	3.33e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PIK3CG—malignant glioma	4.85e-06	3.32e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—TP53—malignant glioma	4.85e-06	3.32e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—VEGFA—malignant glioma	4.83e-06	3.31e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—VEGFA—malignant glioma	4.82e-06	3.3e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—AKT1—malignant glioma	4.82e-06	3.3e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—VEGFA—malignant glioma	4.81e-06	3.29e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—EGFR—malignant glioma	4.79e-06	3.28e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—VEGFA—malignant glioma	4.79e-06	3.28e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—STAT3—malignant glioma	4.78e-06	3.28e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—STAT3—malignant glioma	4.77e-06	3.27e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PIK3CB—malignant glioma	4.77e-06	3.27e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—STAT3—malignant glioma	4.76e-06	3.26e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—KRAS—malignant glioma	4.76e-06	3.26e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—VEGFA—malignant glioma	4.74e-06	3.25e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—STAT3—malignant glioma	4.74e-06	3.25e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—VEGFA—malignant glioma	4.73e-06	3.24e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—KRAS—malignant glioma	4.73e-06	3.24e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PTGS2—malignant glioma	4.73e-06	3.24e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—STAT3—malignant glioma	4.7e-06	3.22e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—STAT3—malignant glioma	4.69e-06	3.21e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PPARG—malignant glioma	4.68e-06	3.21e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—PTEN—malignant glioma	4.59e-06	3.15e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—AKT1—malignant glioma	4.55e-06	3.12e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—KRAS—malignant glioma	4.53e-06	3.1e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—MYC—malignant glioma	4.52e-06	3.1e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Metabolism—PIK3CA—malignant glioma	4.48e-06	3.07e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—MYC—malignant glioma	4.45e-06	3.05e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—MYC—malignant glioma	4.44e-06	3.04e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—MYC—malignant glioma	4.42e-06	3.03e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—EGFR—malignant glioma	4.42e-06	3.03e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—MYC—malignant glioma	4.41e-06	3.02e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PIK3CB—malignant glioma	4.39e-06	3.01e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—PIK3CA—malignant glioma	4.37e-06	2.99e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—MYC—malignant glioma	4.37e-06	2.99e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—AKT1—malignant glioma	4.36e-06	2.98e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—MYC—malignant glioma	4.35e-06	2.98e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PIK3CB—malignant glioma	4.35e-06	2.98e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PTGS2—malignant glioma	4.35e-06	2.98e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—EGFR—malignant glioma	4.35e-06	2.98e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	4.35e-06	2.98e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—EGFR—malignant glioma	4.34e-06	2.97e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—EGFR—malignant glioma	4.33e-06	2.96e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PTGS2—malignant glioma	4.31e-06	2.95e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—EGFR—malignant glioma	4.31e-06	2.95e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—EGFR—malignant glioma	4.27e-06	2.93e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PIK3CD—malignant glioma	4.27e-06	2.92e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—EGFR—malignant glioma	4.26e-06	2.92e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—TP53—malignant glioma	4.23e-06	2.9e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—TP53—malignant glioma	4.2e-06	2.88e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—KRAS—malignant glioma	4.18e-06	2.86e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—PIK3CA—malignant glioma	4.16e-06	2.85e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PTEN—malignant glioma	4.12e-06	2.83e-05	CbGpPWpGaD
Nortriptyline—PTGS1—Metabolism—AKT1—malignant glioma	4.12e-06	2.82e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—CAV1—malignant glioma	4.11e-06	2.82e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—KRAS—malignant glioma	4.11e-06	2.81e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—KRAS—malignant glioma	4.1e-06	2.81e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—AKT1—malignant glioma	4.1e-06	2.81e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—KRAS—malignant glioma	4.09e-06	2.8e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—KRAS—malignant glioma	4.07e-06	2.79e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—KRAS—malignant glioma	4.03e-06	2.76e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—TP53—malignant glioma	4.03e-06	2.76e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—KRAS—malignant glioma	4.02e-06	2.76e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—PIK3CA—malignant glioma	3.84e-06	2.63e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PTEN—malignant glioma	3.79e-06	2.6e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	3.77e-06	2.59e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—PIK3CA—malignant glioma	3.77e-06	2.58e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—PIK3CA—malignant glioma	3.77e-06	2.58e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—PIK3CA—malignant glioma	3.76e-06	2.58e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PTEN—malignant glioma	3.76e-06	2.58e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—PIK3CA—malignant glioma	3.75e-06	2.57e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PIK3CG—malignant glioma	3.75e-06	2.57e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—PIK3CA—malignant glioma	3.74e-06	2.56e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PIK3CB—malignant glioma	3.72e-06	2.55e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—TP53—malignant glioma	3.71e-06	2.54e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—PIK3CA—malignant glioma	3.71e-06	2.54e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—PIK3CA—malignant glioma	3.7e-06	2.53e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PTGS2—malignant glioma	3.68e-06	2.52e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Metabolism—AKT1—malignant glioma	3.66e-06	2.5e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—TP53—malignant glioma	3.65e-06	2.5e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—TP53—malignant glioma	3.64e-06	2.5e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—TP53—malignant glioma	3.63e-06	2.49e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—TP53—malignant glioma	3.62e-06	2.48e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PPARG—malignant glioma	3.61e-06	2.48e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—TP53—malignant glioma	3.59e-06	2.46e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—TP53—malignant glioma	3.58e-06	2.45e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—AKT1—malignant glioma	3.57e-06	2.44e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—AKT1—malignant glioma	3.55e-06	2.43e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—AKT1—malignant glioma	3.4e-06	2.33e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PIK3CD—malignant glioma	3.29e-06	2.26e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—PIK3CA—malignant glioma	3.24e-06	2.22e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PTEN—malignant glioma	3.21e-06	2.2e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—AKT1—malignant glioma	3.13e-06	2.15e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—AKT1—malignant glioma	3.08e-06	2.11e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—AKT1—malignant glioma	3.08e-06	2.11e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—AKT1—malignant glioma	3.08e-06	2.11e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—AKT1—malignant glioma	3.07e-06	2.11e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—AKT1—malignant glioma	3.07e-06	2.1e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—AKT1—malignant glioma	3.06e-06	2.09e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—AKT1—malignant glioma	3.03e-06	2.07e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—AKT1—malignant glioma	3.02e-06	2.07e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PIK3CA—malignant glioma	2.91e-06	1.99e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.87e-06	1.97e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PTGS2—malignant glioma	2.84e-06	1.95e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PIK3CA—malignant glioma	2.68e-06	1.83e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PIK3CA—malignant glioma	2.65e-06	1.82e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—AKT1—malignant glioma	2.65e-06	1.81e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PTEN—malignant glioma	2.48e-06	1.7e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—AKT1—malignant glioma	2.38e-06	1.63e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PIK3CA—malignant glioma	2.27e-06	1.55e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—AKT1—malignant glioma	2.19e-06	1.5e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—AKT1—malignant glioma	2.17e-06	1.48e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—AKT1—malignant glioma	1.85e-06	1.27e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.75e-06	1.2e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—AKT1—malignant glioma	1.43e-06	9.79e-06	CbGpPWpGaD
